| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.02.25 | IRLAB Therapeutics - EMA alignment on mesdopetam Phase III plans | 510 | Edison Investment Research | IRLAB has bolstered the value of its lead programme, mesdopetam in levodopa-induced dyskinesias (PD-LIDs), following confirmation that the European Medicines Agency (EMA) is aligned with the company... ► Artikel lesen | |
| 20.02.25 | Metlen (ASE: MYTIL) FY24 Results | 351 | Edison Investment Research | Metlen's FY24 results released on 20 February were broadly in line with consensus (EBITDA €1,080bn, 0.9% above consensus of €1,070bn and 2.4% above Edison of €1055bn, EPS €4.46, 2.2% below consensus... ► Artikel lesen | |
| 20.02.25 | Mendus - Vididencel on track in AML going into 2025 | 402 | Edison Investment Research | Mendus has reported its FY24 results, reflecting an active period. Lead programme, vididencel in acute myeloid leukaemia (AML), had encouraging data from the ADVANCE II trial in December, laying the... ► Artikel lesen | |
| 20.02.25 | Recce Pharmaceuticals - Positive R327G Phase II ABSSSI study results | 478 | Edison Investment Research | Recce has reported positive results from its open-label Phase II study assessing RECCE® 327 topical gel (R327G) in patients with acute bacterial skin and skin structure infections (ABSSSI), including... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| GERRESHEIMER | 2.602 |
| SAP | 2.228 |
| TUI | 1.507 |
| ALMONTY | 1.360 |
| RHEINMETALL | 1.149 |
| BYD | 1.140 |
| NOVO NORDISK | 1.077 |
| SIEMENS ENERGY | 1.007 |
| DEUTSCHE TELEKOM | 929 |
| PAYPAL | 794 |
| BASF | 786 |
| VONOVIA | 783 |
| DRONESHIELD | 780 |
| STELLANTIS | 774 |
| COMMERZBANK | 713 |
| AMAZON | 675 |
| NVIDIA | 669 |
| BAYER | 611 |
| ALLIANZ | 607 |
| EVOTEC | 556 |
| RENK GROUP | 532 |
| TEAMVIEWER | 532 |
| MICROSOFT | 502 |
| NORDEX | 492 |
| KRAFT HEINZ | 473 |